Literature DB >> 29296695

Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment.

Sara Serra1,2, Tiziana Vaisitti1,2, Valentina Audrito1,2, Cinzia Bologna1,2, Roberta Buonincontri1,2, Shih-Shih Chen3, Francesca Arruga1,2, Davide Brusa2, Marta Coscia4, Ozren Jaksic5, Giorgio Inghirami6,7, Davide Rossi8, Richard R Furman9, Simon C Robson10, Gianluca Gaidano8, Nicholas Chiorazzi3, Silvia Deaglio1,2.   

Abstract

The chronic lymphocytic leukemia (CLL) niche is a closed environment where leukemic cells derive growth and survival signals through their interaction with macrophages and T lymphocytes. Here, we show that the CLL lymph node niche is characterized by overexpression and activation of HIF-1α, which increases adenosine generation and signaling, affecting tumor and host cellular responses. Hypoxia in CLL lymphocytes modifies central metabolic pathways, protects against drug-driven apoptosis, and induces interleukin 10 (IL-10) production. In myeloid cells, it forces monocyte differentiation to macrophages expressing IRF4, IDO, CD163, and CD206, hallmarks of the M2 phenotype, which promotes tumor progression. It also induces IL-6 production and enhances nurturing properties. Low oxygen levels decrease T-cell proliferation, promote glycolysis, and cause the appearance of a population of PD-1+ and IL-10-secreting T cells. Blockade of the A2A adenosine receptor counteracts these effects on all cell populations, making leukemic cells more susceptible to pharmacological agents while restoring immune competence and T-cell proliferation. Together, these results indicate that adenosine signaling through the A2A receptor mediates part of the effects of hypoxia. They also suggest that therapeutic strategies to inhibit the adenosinergic axis may be useful adjuncts to chemotherapy or tyrosine kinase inhibitors in the treatment of CLL patients.

Entities:  

Year:  2016        PMID: 29296695      PMCID: PMC5744057          DOI: 10.1182/bloodadvances.2016000984

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  69 in total

Review 1.  Macrophage plasticity and polarization: in vivo veritas.

Authors:  Antonio Sica; Alberto Mantovani
Journal:  J Clin Invest       Date:  2012-03-01       Impact factor: 14.808

2.  In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells.

Authors:  Bradley T Messmer; Davorka Messmer; Steven L Allen; Jonathan E Kolitz; Prasad Kudalkar; Denise Cesar; Elizabeth J Murphy; Prasad Koduru; Manlio Ferrarini; Simona Zupo; Giovanna Cutrona; Rajendra N Damle; Tarun Wasil; Kanti R Rai; Marc K Hellerstein; Nicholas Chiorazzi
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

Review 3.  Ecto-enzyme and signaling functions of lymphocyte CD73.

Authors:  R Resta; Y Yamashita; L F Thompson
Journal:  Immunol Rev       Date:  1998-02       Impact factor: 12.988

4.  Co-blockade of immune checkpoints and adenosine A2A receptor suppresses metastasis.

Authors:  Arabella Young; Deepak Mittal; Kimberley Stannard; Michelle Yong; Michele Wl Teng; Bertrand Allard; John Stagg; Mark J Smyth
Journal:  Oncoimmunology       Date:  2014-12-15       Impact factor: 8.110

5.  Cutting edge: hypoxia-inducible factor 1alpha and its activation-inducible short isoform I.1 negatively regulate functions of CD4+ and CD8+ T lymphocytes.

Authors:  Dmitriy Lukashev; Boris Klebanov; Hidefumi Kojima; Alex Grinberg; Akiko Ohta; Ludmilla Berenfeld; Roland H Wenger; Akio Ohta; Michail Sitkovsky
Journal:  J Immunol       Date:  2006-10-15       Impact factor: 5.422

Review 6.  Fueling immunity: insights into metabolism and lymphocyte function.

Authors:  Erika L Pearce; Maya C Poffenberger; Chih-Hao Chang; Russell G Jones
Journal:  Science       Date:  2013-10-11       Impact factor: 47.728

7.  A2A adenosine receptor protects tumors from antitumor T cells.

Authors:  Akio Ohta; Elieser Gorelik; Simon J Prasad; Franca Ronchese; Dmitriy Lukashev; Michael K K Wong; Xiaojun Huang; Sheila Caldwell; Kebin Liu; Patrick Smith; Jiang-Fan Chen; Edwin K Jackson; Sergey Apasov; Scott Abrams; Michail Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-17       Impact factor: 11.205

Review 8.  Regulation of CLL survival by hypoxia-inducible factor and its target genes.

Authors:  Idit Shachar; Sivan Cohen; Ayelet Marom; Shirly Becker-Herman
Journal:  FEBS Lett       Date:  2012-07-24       Impact factor: 4.124

9.  The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.

Authors:  Davide Brusa; Sara Serra; Marta Coscia; Davide Rossi; Giovanni D'Arena; Luca Laurenti; Ozren Jaksic; Giorgio Fedele; Giorgio Inghirami; Gianluca Gaidano; Fabio Malavasi; Silvia Deaglio
Journal:  Haematologica       Date:  2013-01-08       Impact factor: 9.941

10.  Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104.

Authors:  Juliana Benito; Yuexi Shi; Barbara Szymanska; Hernan Carol; Ingrid Boehm; Hongbo Lu; Sergej Konoplev; Wendy Fang; Patrick A Zweidler-McKay; Dario Campana; Gautam Borthakur; Carlos Bueso-Ramos; Elizabeth Shpall; Deborah A Thomas; Craig T Jordan; Hagop Kantarjian; William R Wilson; Richard Lock; Michael Andreeff; Marina Konopleva
Journal:  PLoS One       Date:  2011-08-11       Impact factor: 3.240

View more
  18 in total

Review 1.  Adenosinergic signaling as a target for natural killer cell immunotherapy.

Authors:  Jiao Wang; Sandro Matosevic
Journal:  J Mol Med (Berl)       Date:  2018-08-01       Impact factor: 4.599

2.  HIF-1α: a potential treatment target in chronic lymphocytic leukemia.

Authors:  Martina Seiffert
Journal:  Haematologica       Date:  2020-04       Impact factor: 9.941

3.  B-cell Receptor Signaling Induced Metabolic Alterations in Chronic Lymphocytic Leukemia Can Be Partially Bypassed by TP53 Abnormalities.

Authors:  Katarina Kluckova; Andrew J Clear; Annalisa D'Avola; Laura Z Rassenti; Thomas J Kipps; John G Gribben; John C Riches
Journal:  Hemasphere       Date:  2022-05-13

4.  Reprogramming Tumor-Immune Cell Interface in Solid and Hematological Malignancies to Enhance Response to Therapy.

Authors:  Maria Teresa Di Martino; Francesca Zazzeroni; Massimo Donadelli; Claudia Chiodoni; Michele Caraglia; Katia Scotlandi; Stefania Meschini; Carlo Leonetti
Journal:  J Exp Clin Cancer Res       Date:  2018-03-05

Review 5.  Targeting Adenosine Receptor Signaling in Cancer Immunotherapy.

Authors:  Kevin Sek; Christina Mølck; Gregory D Stewart; Lev Kats; Phillip K Darcy; Paul A Beavis
Journal:  Int J Mol Sci       Date:  2018-12-02       Impact factor: 5.923

Review 6.  NAD-Biosynthetic and Consuming Enzymes as Central Players of Metabolic Regulation of Innate and Adaptive Immune Responses in Cancer.

Authors:  Valentina Audrito; Antonella Managò; Federica Gaudino; Leonardo Sorci; Vincenzo Gianluca Messana; Nadia Raffaelli; Silvia Deaglio
Journal:  Front Immunol       Date:  2019-07-25       Impact factor: 7.561

Review 7.  Ectonucleotidases in Blood Malignancies: A Tale of Surface Markers and Therapeutic Targets.

Authors:  Tiziana Vaisitti; Francesca Arruga; Giulia Guerra; Silvia Deaglio
Journal:  Front Immunol       Date:  2019-10-04       Impact factor: 7.561

8.  HIF-1α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia.

Authors:  Valentina Griggio; Candida Vitale; Maria Todaro; Chiara Riganti; Joanna Kopecka; Chiara Salvetti; Riccardo Bomben; Michele Dal Bo; Daniela Magliulo; Davide Rossi; Gabriele Pozzato; Lisa Bonello; Monia Marchetti; Paola Omedè; Ahad Ahmed Kodipad; Luca Laurenti; Giovanni Del Poeta; Francesca Romana Mauro; Rosa Bernardi; Thorsten Zenz; Valter Gattei; Gianluca Gaidano; Robin Foà; Massimo Massaia; Mario Boccadoro; Marta Coscia
Journal:  Haematologica       Date:  2019-07-09       Impact factor: 9.941

9.  Optimized Xenograft Protocol for Chronic Lymphocytic Leukemia Results in High Engraftment Efficiency for All CLL Subgroups.

Authors:  Sarah Decker; Anabel Zwick; Shifa Khaja Saleem; Sandra Kissel; Andres Rettig; Konrad Aumann; Christine Dierks
Journal:  Int J Mol Sci       Date:  2019-12-12       Impact factor: 5.923

Review 10.  Targeting the Adenosinergic Axis in Chronic Lymphocytic Leukemia: A Way to Disrupt the Tumor Niche?

Authors:  Tiziana Vaisitti; Francesca Arruga; Silvia Deaglio
Journal:  Int J Mol Sci       Date:  2018-04-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.